个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study

| 导出 |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Bi, L.[1] * ; Li, Y.[2] ; He, L.[3] ; Xu, H.[4] ; Jiang, Z.[5] ; Wang, Y.[6] ; Li, X.[7] ; Wei, W.[8] ; Gu, J.[9] ; Wang, G.[10] ; Zhang, Z.[11,25] ; Zhou, B.[12] ; Liu, Y.[13] ; Wu, Z.[14] ; Liu, H.[15] ; He, D.[16] ; Lv, Z.[17] ; Li, Z.[2,18] ; Zuo, X.[19] ; Dong, L.[20] ; Wu, H.[21] ; Zhang, H.[22] ; Chen, H.[23] ; Bao, C.[24] ; Zhang, Z.[11,25] ; Zhang, M.[26] ; Song, H.[27] ; Zheng, Y.[28] ; Jiang, L.[29] ; Liu, X.[30] ; Boehnlein, M.[31] ; Dunkel, J.[31] ; Shao, J.[32] ; Harris, K.[33] ; Li, Z.[2,18] ;
机构： [1]Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China; [2]Peking Univ, Peoples Hosp, Beijing, Peoples R China; [3]Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [4]Shanghai Changzheng Hosp, Shanghai, Peoples R China; [5]Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China; [6]Inner Mongolia Univ Sci & Technol, Baotou Med Coll, Affiliated Hosp 1, Baotou, Peoples R China; [7]Anhui Med Univ, Anhui Prov Hosp, Hefei, Anhui, Peoples R China; [8]Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China; [9]Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [10]China Japan Friendship Hosp, Beijing, Peoples R China; [11]Harbin Med Univ, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China; [12]Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China; [13]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China; [14]Xijing Hosp, Xian, Shaanxi, Peoples R China; [15]Shandong Univ, Qilu Hosp, Jinan, Shandong, Peoples R China; [16]Guanghua Hosp, Shanghai, Peoples R China; [17]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China; [18]First Affiliated Hosp, Bengbu Med Coll, Bengbu, Peoples R China; [19]Cent S Univ, Xiangya Hosp, Changsha, Peoples R China; [20]Huazhong Univ, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [21]Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China; [22]Cent S Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [23]Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China; [24]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China; [25]Peking Univ, Hosp 1, Beijing, Peoples R China; [26]Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China; [27]Beijing Ji Shui Tan Hosp, Beijing, Peoples R China; [28]Beijing Chao Yang Hosp, Beijing, Peoples R China; [29]Fudan Univ, Zhong Shan Hosp, Shanghai, Peoples R China; [30]Peking Univ, Hosp 3, Beijing, Peoples R China; [31]UCB Pharma, Monheim, Germany; [32]UCB Pharma, Tokyo, Japan; [33]UCB Pharma, Slough, Berks, England; [34]Peking Univ, Peoples Hosp, Dept Rheumatism Immun, 11 Xizhimen South St, Beijing, Peoples R China
出处：
ISSN：

关键词： tumour necrosis factor-alpha DMARD certolizumab pegol rheumatoid arthritis Chinese

摘要：
Objective To evaluate the efficacy and safety of certolizumab pegol (CZP) in combination with methotrexate (MTX) in Chinese patients with active rheumatoid arthritis (RA) and an inadequate response to MTX. Methods This 24-week, phase 3, double-blind, placebo-controlled study was conducted in 30 centres across China. A total of 430 patients were randomised 3: 1 to receive CZP 200 mg every 2 weeks (loading dose: 400 mg CZP at Weeks 0, 2 and 4) plus MTX or placebo (PBO) plus MTX. The primary endpoint was ACR20 response at Week 24, for which the superiority of CZP+MTX over PBO+MTX was evaluated. Additional parameters for clinical efficacy, health outcomes, immunogenicity and safety were assessed. Results At Week 24, 54.8% of CZP+MTX patients and 23.9% of PBO+MTX patients achieved ACR20 (odds ratio: 3.9, p<0.001). CZP+MTX patients also achieved greater improvements in HAQ-DI, higher ACR50/70 responses and higher DAS28(ESR) remission rate at Week 24. Rapid onset of response to CZP+MTX was observed as early as Week 1 for most of the clinical, functional and patient-reported outcomes. Incidences of treatment-emergent adverse events (TEAEs) were similar between treatment arms. Serious TEAEs were reported by 6.3% of CZP+MTX patients and 2.7% of PBO+MTX patients. No new safety signals were observed. Conclusion CZP in combination with MTX showed an acceptable safety profile, a rapid onset of response and sustained effects in reducing the signs and symptoms of RA and improving physical function in Chinese patients with RA and an inadequate response to MTX.

基金：
UCB PharmaUCB Pharma SA
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 3 区 医学
小类 | 3 区 风湿病学
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 风湿病学
JCR分区：
出版当年[2019]版：
Q2 RHEUMATOLOGY
最新[2023]版：
Q2 RHEUMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China;
通讯作者：
通讯机构： [34]Peking Univ, Peoples Hosp, Dept Rheumatism Immun, 11 Xizhimen South St, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Bi L.,Li Y.,He L.,et al.Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study[J].CLINICAL AND EXPERIMENTAL RHEUMATOLOGY.2019,37(2):227-234.
APA：
Bi, L.,Li, Y.,He, L.,Xu, H.,Jiang, Z....&Li, Z..(2019).Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,37,(2)
MLA：
Bi, L.,et al."Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study".CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 37..2(2019):227-234

相关文献

[1]Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients [2]Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study. [3]Kunxian for the Treatment of Rheumatoid Arthritis [4]室性心律失常与血清TNF-α和高敏C反应蛋白水平的相关性研究 [5]Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE. [6]Association of TLR4 gene non-missense single nucleotide polymorphisms with rheumatoid arthritis in Chinese Han population [7]Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE [8]不对称二甲基精氨酸对THP-1源性巨噬细胞表达MIF和分泌TNF-α、IL-8的影响 [9]Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study [10]An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis (RA-BEYOND)

资源点击量：56917 今日访问量：0 总访问量：1772 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)